key: cord-1015409-ypqusgs3
authors: Lozano-Ojalvo, Daniel; Camara, Carmen; Lopez-Granados, Eduardo; Nozal, Pilar; Pino-Molina, Lucía del; Bravo-Gallego, Yadira; Paz-Artal, Estela; Pion, Marjorie; Correa-Rocha, Rafael; Ortiz, Alberto; Lopez-Hoyos, Marcos; Iribarren, Marta Erro; Portoles, Jose; Rojo-Portoles, Maria Pilar; Ojeda, Gloria; Cervera, Isabel; Gonzalez-Perez, Maria; Bodega-Mayor, Irene; Montes-Casado, Maria; Portoles, Pilar; Perez-Olmeda, Mayte; Oteo, Jesus; Sanchez-Tarjuelo, Rodrigo; Pothula, Venu; Schwarz, Megan; Brahmachary, Manisha; Tan, Anthony Tanoto; Le Bert, Nina; Berin, Cecilia; Bertoletti, Antonio; Guccione, Ernesto; Ochando, Jordi
title: Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals
date: 2021-08-04
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.109570
sha: 6db47aec5a633272cdd1e0b205d5b2fdf8327262
doc_id: 1015409
cord_uid: ypqusgs3

The rapid development of mRNA-based vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to the design of accelerated vaccination schedules that have been extremely effective in naïve individuals. While a two-dose immunization regimen with the BNT162b2 vaccine has been demonstrated to provide a 95% efficacy in naïve individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has not been investigated in detail. Here we characterize, SARS-CoV-2 spike-specific humoral and cellular immunity in naïve and previously infected individuals during and after two-doses of BNT162b2 vaccination. Our results demonstrate that, while the second dose increases both the humoral and cellular immunity in naïve individuals, COVID-19 recovered individuals reach their peak of immunity after the first dose. These results suggests that a second dose, according to the current standard regimen of vaccination, may be not necessary in individuals previously infected with SARS-CoV-2.

The rapid development of mRNA-based vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to the design of accelerated vaccination schedules that have been extremely effective in naïve individuals. While a two-dose immunization regimen with the BNT162b2 vaccine has been demonstrated to provide a 95% efficacy in naïve individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has not been investigated in detail. Here we characterize, SARS-CoV-2 spike-specific humoral and cellular immunity in naïve and previously infected individuals during and after two-doses of BNT162b2 vaccination. Our results demonstrate that, while the second dose increases both the humoral and cellular immunity in naïve individuals, COVID-19 recovered individuals reach their peak of immunity after the first dose. These results suggests that a second dose, according to the current standard regimen of vaccination, may be not necessary in individuals previously infected with SARS-CoV-2. vaccine was authorized for emergency use by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in December 2020 (Krammer, 2020) . The vaccination strategy for the BNT162b2 vaccine involves an accelerated two-dose vaccination regimen administered 21 days apart, which has been demonstrated to induce a spike-specific humoral and cellular immunity associated with a 95% efficacy in naïve individuals (Polack et al., 2020) . However, in individuals with prior exposure to SARS-CoV-2, the utility of the second dose has been challenged. While robust spike-specific antibodies and T cells are induced by a single dose vaccination in SARS-CoV-2 seropositive individuals (Krammer et al., 2021; Prendecki et al., 2021) , the second vaccination dose does not appear to further increase the spike-specific humoral response in COVID-19 recovered individuals (Samanovic et al., 2021) .

The effects of the second dose mRNA vaccine on spike-specific T cell response has just started to be investigated in both naïve and in SARS-CoV-2 pre-exposed individuals. Understanding spike-specific T cell response is critical, as protection from disease severity and infection are likely to be dependent on the coordinated activation of both the humoral and cellular arms of adaptive immunity (McMahan et al., 2021) . However, the complexity of monitoring the T cell magnitude and function has so far prevented the measurement of the immune cellular parameters in a robust number of vaccinated individuals during the full vaccination schedule. To address this problem, we investigated spike-SARS-CoV-2 antigen specific T cell responses in naïve and COVID-19 recovered individuals during full BNT162b2 mRNA vaccination.

J o u r n a l P r e -p r o o f

We first investigated the spike-specific T cell response by a spectral flow cytometric analysis using peripheral blood mononuclear cells (PBMCs) stimulated in vitro with DMSO or SARS-CoV-2 spike (S) peptide pool (Le in naïve and COVID-19 recovered individuals before and after vaccination (20 days after the second dose). We observed that Spike-specific (CD154 + ) memory (CD45RA -CCR7 -) CD4 + T cells producing both IFN- and IL-2 were present in COVID-19 recovered individuals, as well as in naïve subjects 20d after vaccination (Supp. Figs.1A-B) . Functional phenotyping of these cells revealed that spike-specific IFN- and IL-2 secreting CD4 + T cells are mainly represented by Th1 (CCR6 -CCR4 -CXCR3 + ) cells (Supp.

We next analyzed the dynamic changes of functional spike-specific T cell response by measuring the quantity of IFN- and IL-2 present in whole blood stimulated with a Spike peptide pool (Le . In contrast to more complex and detailed flow cytometry based analysis that require larger amounts of blood, this approach requires only 1 ml of blood, which facilitates multiple longitudinal tests in a single individual and reliable quantified SARS-CoV-2specific T cells in SARS-CoV-2 infected individuals (Le and vaccine recipients (Kalimuddin et al., 2021) . Figure 1 shows the results obtained in 92 individuals with and without previous documented SARS-CoV-2 infection (47 naïve; mean age 39.9 years [range, 20 to 62], female 78%) and 45 PCR/antigen test-confirmed SARS-CoV-2 recovered (39% at 6-9 months after infection, 26% 3-6 months, 35% 1-3 months) (mean age 44.3 years [range, 20 to 76]; female 76%) ( Table 1) , tested at multiple time points (i.e. prior to, and 10 and 20 days after the first and second dose of vaccine).

Prior to vaccination, the spike peptide pool induced in whole blood a higher IFN- production in COVID-19 recovered individuals than in naïve subjects (median pre-vaccination in naïve: 1.0 pg/ml [N=20] and in COVID-19 recovered: 46.9 pg/ml [N=21]) (Fig.1A) . We observed a similar trend in spike-specific IL-2 production (median pre-vaccination in naïve: 0.5 pg/ml [N=20] and COVID-19 recovered: 56.9 pg/ml [N=21]) ( Fig.1B) ( Table 1) . Evaluation of the spike-specific T cell response 10 days after the first dose indicates that COVID-19 recovered individuals mount a stronger IFN- and IL-2 response in comparison with naïve subjects (median day 10 post-first vaccine dose in naïve: 109.5 pg/ml [N=20] and in COVID-19 recovered: 547.8 pg/ml [N=21] for IFN-; naïve: 15.85 pg/ml [N=16] and COVID-19 recovered: 76.9 pg/ml [N=21] for IL-2) (Figs.1A-B). COVID-19 recovered individuals maintain their T cell immunity on day 20 post-first vaccine dose, while IFN- response in naïve individuals decreases although is not statistically significant (median day 20 post-first vaccine dose in naïve: 52.9 pg/ml [N=23] and in COVID-19 recovered: 351.3 pg/ml [N=21]). A similar trend in spike-specific IL-2 production was observed, although no decrease was seen in naïve individuals (median day 20 post-first vaccine dose in naïve: 127.0 pg/ml [N=22] and in COVID-19 recovered: 223.5 pg/ml [N=20]). These results indicate that individuals with pre-existing immunity exert a more potent and sustained T cell response to SARS-CoV-2 spike after the first dose of the vaccine, consistent with recent investigations (Tauzin et al., 2021) , (Painter et al., 2021) .

We next studied the effects of the second dose of the vaccine. Sampling on day 10 after the second dose confirmed the beneficial effects of the recall vaccine in naïve individuals who increase their IFN- and IL-2 (median day 10 post-second vaccine dose in naïve: 211.8 pg/ml [N=20] for IFN- and 187.0 pg/ml [N=16] for IL-2). On the contrary, COVID-19 recovered individuals did not increase their IFN- or IL-2 production on day 10 after the second vaccine dose (median day 10 post-second vaccine dose in COVID-19 recovered: 212.0 pg/ml [N=21] for IFN- and 148.5 pg/ml [N=18] for IL-2). These findings indicate that, while naïve subjects significantly increase their immunity against SARS-CoV-2 spike protein after the second dose of J o u r n a l P r e -p r o o f the vaccine, COVID-19 recovered individuals do not seem to benefit from the standard regimen for COVID-19 vaccination. Interestingly, we observed that, while IFN- secretion in COVID-19 recovered individuals decreases on day 20 after the second dose, IL-2 levels are not decreased (median day 20 post-first vaccine dose in naïve: 87.0 pg/ml [N=23] and in COVID-19 recovered: 136.1 pg/ml [N=23] for IFN-; naïve: 121.5 pg/ml [N=24] and COVID-19 recovered: 86.4 pg/ml [N=23] for IL-2), which suggests that IL-2 secretion by Spike-specific Th1 cells might represent a better biomarker to measure T cell immunity in vaccinated individuals (Figs.1A-B and Table  1 ).

Our analysis of the humoral response depicts a similar trend when measuring SARS-CoV-2 spike-specific IgG levels, which indicates that naïve individuals achieve significant concentrations of IgG antibodies after the second vaccine dose (Fig.1C ). This suggests that protection is achieved following the standard two-dose regimen for COVID-19 vaccination in naïve individuals, consistent with a recent report (Ebinger et al., 2021) . On the contrary, COVID-19 recovered individuals reach the peak of the response on day 10 after the first dose, which is consistent with the cellular response observed in Figs.1A-B . We also observed a better correlation between IL-2 and IgG in comparison to IFN- and IgG (Supp. Fig.2) , which supports the potential use of IL-2 as biomarker for cellular immunity.

J o u r n a l P r e -p r o o f DISCUSSION From our studies of the humoral and cellular spike-specific immunity in recipients of the BNT162b2 mRNA COVID-19 vaccine we conclude that a single dose of the vaccine elicits the generation of specific antibodies and a T cell immune response in naïve and COVID-19 recovered individuals, consistent with recently published data (Prendecki et al., 2021; Tauzin et al., 2021) . In naïve subjects, the T cell response is boosted in conjunction with spike-specific IgG levels after the second dose. On the contrary, the second vaccine dose not increase the spike-specific T cell response in individuals with a pre-existing immunity against SARS-CoV-2 and further evidences that a single dose vaccine is sufficient to induce a protective immunity in Covid-19 recovered individuals (Reynolds et al., 2021) .

Overall, our data support the vaccination scheme determined in clinical trials with prompt administration of the second dose in individuals without previous SARS-CoV-2 exposure (Kadire et al., 2021) , but suggest that in individuals with pre-existing immunity against SARS-CoV-2 the second dose of the vaccine may not be necessary. Longitudinal evaluation of the humoral and cellular immunity, especially in naïve individuals with reduced response to mRNA SARS-CoV-2 BNT162b2 (Grupper et al., 2021) , may also justify the need for a third vaccination dose to boost the immune response in immunosuppressed individuals (Kamar et al., 2021) . At present, there is a shortage of doses to vaccinate a large proportion of the population and public health authorities are designing priority vaccination strategies according to age, comorbidities and risk assessment criteria. The present data supports a single vaccine dose in COVID-19 recovered individuals. [prevaccination (pre) , 10 and 20 days after the first vaccine dose (10 and 20, respectively), and 10 and 20 days after the second vaccine dose (30 and 40, respectively)] after overnight stimulation of whole blood with SARS-CoV-2 peptide pools. IFN- and IL-2 concentration was determined using ELLA single plex cartridges (n=92 individuals; 47 naïve and 45 COVID-19 recovered). c) Kinetics of SARS-CoV-2 spikespecific IgG serum levels in naïve and COVID-19 recovered individuals measured by ACCESS SARS-CoV-2 CLIA. For IgG, IFN-y and IL-2 determination, group means method was used to compare pretreatment vs post-treatment time points and also among post treatment timepoints. All individual timepoints were measured using technical triplicates. Two sample t-test assuming unpaired populations for pre-and post-treatment was performed for each of the markers, separately for the COVID-19 recovered and naive cohorts. The p-value for the test statistic was set to 0.05 level of significance and BH method was used for multiple testing correction.

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jordi Ochando (Jordi.ochando@mssm.edu).

Further information and requests for resources and reagents should be directed to Jordi Ochando (Jordi.ochando@mssm.edu). This study did not generate new unique reagents.

 All data reported in this paper will be shared by the lead contact upon request.  This paper does not report original code.

 Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

Peripheral blood samples were obtained from healthy naïve and COVID-19 recovered donors. Peripheral blood samples for humoral and cellular immunity antibody isolation were obtained from male and female donors, and the information of individuals are in Table 1 . Age of these patients are undisclosed due to privacy policy. The study protocols for the collection of clinical specimens from individuals with and without SARS-CoV-2 infection were reviewed and approved by Hospital La Paz, Hospital 12 de Octubre, Hospital Gregorio Marañón, IIS-Fundación Jimenez Díaz, Hospital Universitario Marqués de Valdecilla-IDIVAL and Hospital Puerta de Hierro Clinical Research Ethics Committee (CEIm), and Mount Sinai Hospital Institutional Review Board (IRB). All the study participants provided their written informed consent for the collection of the samples and their subsequent analysis.

SARS-CoV-2 peptide pools of 15-mers (55 peptides) covering 40.5% of the spike (S) protein contain most of the SARS-CoV2 spike epitope published to date (Grifoni et al., 2020) or pools of Prot S/S1/S+ from Miltenyi, were used as reported in (Le .

Whole blood culture with SARS-CoV-2 peptide pools 320 μl of whole blood drawn on the same day were mixed with 80 μl RPMI and stimulated with pools of SARS-CoV-2 peptides (S; 2 μg/ml) or DMSO control. After 15 hours of culture, the supernatant (plasma) was collected and stored at -80ºC until quantification of cytokines.

Cytokine concentrations in the plasma were quantified using Ella with microfluidic multiplex cartridges measuring IFN-γ and IL-2 following the manufacturer's instructions (ProteinSimple, San Jose, California). The level of cytokines present in the plasma of DMSO controls was subtracted from the corresponding peptide pool stimulated samples.

The ACCESS SARS-CoV-2 CLIA (Beckman Coulter Inc., California, USA) was used for semiquantitative detection of IgG directed against S protein RBD using serum obtained from venipuncture blood. Samples were tested on a UniCel Dxl 800 high-performance analyser.

Peripheral blood mononuclear cells (PBMCs) were isolated by means of density centrifugation with Ficoll-Paque Plus (GE Healthcare, Pittsburgh, PA), frozen, and stored in liquid nitrogen until further use. For activation assays, thawed PBMCs were cultured in AIM-V medium (Gibco, Grand Island, NY) with 2.5% AB human serum (Gemini Bio-Products, Inc., West Sacramento, CA), unstimulated (DMSO) or stimulated with SARS-CoV-2 spike (S) peptide pool ( 

Illustrations were prepared using Graphpad Prism (v9) and Cytobank (https://cytobank.org/) and statistical analyses were conducted by Graphpad Prism (v9). For IgG, IFN-y and IL-2 determination, group means method was used to compare pre-treatment vs post-treatment time points and also among post treatment timepoints. Two sample t-test assuming unpaired populations for pre-and post-treatment was performed for each of the markers, separately for the COVID-19 recovered and naive cohorts. The p-value for the test statistic was set to 0.05 level of significance and BH method was used for multiple testing correction. Correlations (Suppl. Fig.2) were estimated by nonparametric Spearman r correlation coefficient and significance was calculated by two tailed p value (indicated in each plot).

-SARS-CoV-2 antigen-specific CD4 + CD154 + Th1 cells secrete IL-2 and IFN -T cell mediated IL-2 and IFN correlate with SARS-CoV-2 IgG humoral immunity -Naïve subjects reach their peak of immunity after the second vaccine dose -COVID-19 recovered individuals reach their peak of immunity after the first vaccine dose n/a 6-9 (39%), 3-6 (26%), 1-3 (35%)

IFN-g (median, pg/ml)

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2

BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus

Delayed Second Dose versus Standard Regimen for Covid-19 Vaccination

Early T cell and binding antibody responses are associated with Covid-19 RNA vaccine efficacy onset

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

SARS-CoV-2 vaccines in development

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection

Correlates of protection against SARS-CoV-2 in rhesus macaques

Rapid induction of antigen-specific CD4<sup>+</sup> T cells guides coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination. bioRxiv

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine

Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS

A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses

We acknowledge the technical contribution of Arroyo Sánchez, Daniel; Baranda, Jana; Baztan-Morales, Sara; Castillo de la Osa, María; Comins-Boo, Alejandra; del Álamo Mayo, Carmen; Gil-Manso, Sergio; Gonzalez Beatriz; Hatem, Sandra; Irure-Ventura, Juan; Miguens, Iria; Muñoz Martinez, Sara; Pereira, Monica; Rodrigues-Guerreiro, Catarina; Rodriguez-Garcia, Mercedes; and San Segundo, David. We would also like to acknowledge Beckman Coulter for donating the equipment required for the determination of spike-specific IgG antibodies. Research reported in this publication was supported in part by National Cancer Institute of the NIH (5R01HD102614-02; R01CA249204 and R01CA248984) and ISMMS seed fund to EG. The authors gratefully acknowledge use of the services and facilities of the Tisch Cancer Institute supported by the NCI Cancer Center Support Grant (P30